Navigation Links
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Date:6/16/2009

#HHSN272200700035C, from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Service.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare, and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids, and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection, and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro, and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.

About Elusys

Based in Pine Brook, New Jersey, Elusys is a private biotechnology company developing antibody therapeutics for treatment of infectious disease. Elusys has been active in the development of biowarfare countermeasures since 2001 and since then has worked in partnership with the US government to develop Anthim for the treatment of anthrax infection. For more information, please visit www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... (PRWEB) September 01, 2014 The B-cell ... growth across six major markets (the US, France, Italy, ... 2013 to $5.41 billion by 2018. , The competitive ... France, Italy, Germany, Spain and the UK is poised ... Disease management of the four largest B-cell NHL indications, ...
(Date:9/1/2014)... September 2014: Permanent atrial fibrillation (AF) doubles the risk ... in more than 6 000 patients presented at ESC ... findings suggest that a simple clinical assessment of the ... stroke risk. , Ischaemic stroke is the second cause ... million deaths and many more disabled patients each year. ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... can lay siege on the victim's disposition and way of ... of coolness can act as an effective pain// reliever. Scientists ... that enable feelings of coolness, and bring immense relief to ... for improved treatment measures for people suffering long-term pain, as ...
... President of the Canadian Medical Association (CMA) said that Canadian ... health of their own children// although in general they rated ... to a survey carried out by Ipsos-Reid, commissioned by the ... kids aged 2-17 are obese/overweight, however only 9% of Canadian ...
... are high during air travel, and not with other forms of ... blood clots can from during any form of travel where the ... has revealed that traveling for more than four hours by air, ... This was substantiated when the research team analyzed 2000 people, who ...
... phobia or fear of needles can be overcome by ... to researchers at the University of New Mexico's// (UNM) ... needles can impact the care a patient receives. ... of needles, whereas some adults avoid the doctor's office ...
... institutions claim to have found that nearly 19% of ... to a direct// result of war. ,Now ... would get the proper treatment necessary. Their fears see ... now mental health treatment from the Department of Veterans ...
... every month for several problems ranging from arthritis to ... enrolled// in Medicare Part D, the new federal prescription-drug ... plan paid for most of their drugs, minus $20 ... coverage stopped. Donna was told by a pharmacist that ...
Cached Medicine News:Health News:American War Veterans Not Receiving Enough Care For PTSD 2Health News:Many American senior citizens fall into the “Doughnut Hole” 2Health News:Many American senior citizens fall into the “Doughnut Hole” 3Health News:Many American senior citizens fall into the “Doughnut Hole” 4
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
Inquire...
... injectable implant that contains microparticles ... biodegradable, synthetic polymer from the ... prior to use by the ... Injection, USP (SWFI) to form ...
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo...
... This new Suction Massage System has been ... areas, such as thighs, buttocks and hips. ... the lymph system, mobilizing excess fluids in ... Initially, we recommend using CELLUSSAGE daily, for ...
Medicine Products: